The Legal Pro Forum, one of the most significant regional events at the intersection of law and business, was held today, organized by Harmonius, an association of scholars and researchers in the field of legal studies. The company Heliant had the opportunity to participate as one of the panellists and contribute to the discussion on one of the most relevant topics of today – the increasingly blurred line between market principles and healthcare ethics.
The panel titled “Who Came First: The Consumer or the Patient? Where Are the Limits of Market Logic in the fields of Healthcare and Pharmaceuticals?”, held as part of the Healthpharm program, brought together legal experts, representatives of pharmaceutical companies, and healthcare professionals. One of the panellists, Vukašin Radulović, Director of Heliant, emphasized the importance of maintaining a balance between market efficiency and social responsibility.
“Digitalization and market models can improve the healthcare system, but they must not undermine its essence – the trust of patients and their right to care that is not driven solely by market interests. Our task, as technological innovators in healthcare, is to show that efficiency and ethics can and must go hand in hand.”
Other panel participants included Danilo Mijušković (Merck Group) and Ljubiša Vulić (Legal & Compliance, Clinical Trials), while the discussion was moderated by Radomir Cerović from Roche.
Panelists: Ljubiša Vulić (Legal & Compliance, Clinical Trials), Danilo Mijušković (Merck Group), moderator Radomir Cerović (Roche) and Vukašin Radulović (Heliant)
The discussion raised a number of important questions about the future of healthcare and pharmaceutical systems, particularly in the context of European regulations, digitalization, and the changing relationship of patients toward their own health. Participants explored how market principles operate within the healthcare and pharmaceutical sectors, where stakeholders are simultaneously patients and consumers of services or products.
For Heliant, participation in this panel represented an opportunity to contribute to the development of sustainable and ethical market models in healthcare, where the patient, trust, and transparency were at the heart of every process.